The Swedish biotech’s successful launch in the US of Tarpeyo for immunoglobulin A nephropathy is progressing well and a Chinese approval is on the horizon as partner Everest’s application is accepted by regulators.

Phase II data position cemdisiran well for Phase III, but several agents are already well ahead. However, Alnylam foresees a polypharmacy approach.

A shift in investor sentiment in 2021 hit Everest hard when it was expanding the commercial team for cancer drug Trodelvy. Entering 2022, the sustained downturn in the capital market environment eventually changed the way the Chinese biotech considers launching drugs in the market.

Roche is not disclosing Phase II results yet, but must exceed late-stage rival drug’s 50% reduction in protein build up to compete in immunoglobulin A nephropathy.